Therapy News and Research

RSS

New alliance for discovery of WNT pathway inhibitors to be used in cancer therapy

Cancer Research Technology (CRT), Merck Serono, a division of Merck KGaA, Darmstadt, Germany, Cancer Research UK, Cardiff University and The Institute of Cancer Research (ICR) are set to begin a major new research collaboration for the first time. This will provide substantial investment in research on the WNT signalling pathway in the hope of finding new drug targets.

15 Jul 2009

Focusing HIV treatment helps control concurrent hepatitis B infection

Prolonged use of highly active antiretroviral therapy (HAART) to treat people infected with both HIV and hepatitis B (HBV) helps to better control the hepatitis B infection and could delay or prevent liver complications, according to a new study by researchers at Wake Forest University School of Medicine.

15 Jul 2009

Skin cancer researchers throw new light on tumour growth

Three researchers from the Dermatology Research Foundation at the University of Sydney have identified a compound produced by certain fatal skin cancer tumours, providing new hope for developing treatments.

14 Jul 2009

Brain imaging (MRI/PET) bring us closer to earlier detection of Alzheimer's

Changes in the brain measured with MRI and PET scans, combined with memory tests and detection of risk proteins in body fluids, may lead to earlier and more accurate diagnosis of Alzheimer's, according to new research reported today at the Alzheimer's Association 2009 International Conference on Alzheimer's Disease (ICAD 2009) in Vienna.

14 Jul 2009

Results from trials of DHA in Alzheimer's and age-related cognitive decline

Results from two large studies using DHA, an omega 3 fatty acid, were reported today at the Alzheimer's Association 2009 International Conference on Alzheimer's Disease (ICAD 2009) in Vienna.

12 Jul 2009

Relationship between migraine history and breast cancer risk among premenopausal and postmenopausal women

The relationship between migraine headaches in women and a significant reduction in breast cancer risk has been confirmed in a follow-on study to landmark research published last year and conducted by scientists at Fred Hutchinson Cancer Research Center. The new study found a 26 percent reduced risk of breast cancer among both premenopausal and postmenopausal women with a clinical diagnosis of migraines.

9 Jul 2009

Multaq approved for atrial fibrillation by FDA

Sanofi-aventis announced today that the U.S. Food and Drug Administration (FDA) has approved Multaq (dronedarone) 400 mg Tablets. Patients with atrial fibrillation (AF) or atrial flutter (AFL) soon will have a new treatment option to help improve current management of their disease. Multaq is the first drug approved in the United States that has shown a clinical benefit to reduce cardiovascular hospitalization in patients with AF/AFL.

7 Jul 2009

NDA for Exenatide once weekly accepted for FDA review

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced that the New Drug Application (NDA) for exenatide once weekly has been accepted for review by the U.S. Food and Drug Administration (FDA).

7 Jul 2009

Review of addiction to prescription painkillers

Chemical dependency and recovery in patients and physicians are closely examined in a series of articles and editorials in the July 2009 issue of Mayo Clinic Proceedings. The subject is especially timely. As the immense challenges, including potential tragedies, of prescription chemical addiction and abuse are being discussed, these articles offer crucial overview, direction and optimism.

7 Jul 2009

Multiple session early psychological interventions for the prevention of post-traumatic stress disorder

Psychological interventions intended to prevent the development of post-traumatic stress disorder (PTSD) in the early stages after a traumatic experience have not been shown to be effective, Cochrane Researchers have concluded. This systematic review focused on multiple-session treatments for everyone involved, irrespective of the presence of symptoms. Two previous reviews found single session interventions to be ineffective.

7 Jul 2009

The effects of antimicrobial therapy on bacterial vaginosis in non-pregnant women

Antimicrobial treatments for bacterial vaginosis (BV) are effective, but taking lactobacillus tablets alongside metronidazole antibiotic therapy increases effectiveness over taking this antibiotic alone, according to a Cochrane Systematic Review. The researchers also concluded that intravaginal lactobacillus was as effective as oral metronidazole, although they did note unexplained drop-outs from the trials.

7 Jul 2009

Progressive resistance strength training for improving physical function in seniors

Progressive resistance strength training not only helps older adults become stronger but also makes their everyday life easier, a Cochrane Review suggests.

7 Jul 2009

Artemisinin-based combination therapy for treating uncomplicated malaria

Current combination malaria therapies recommended by the World Health Organisation (WHO) provide adequate treatment for mild malaria, according to a Cochrane Systematic Review of the evidence. However, selected trials had high failure rates for some combinations and evidence for the effectiveness of anti-malarial therapies is lacking in some vulnerable groups.

7 Jul 2009

High-intensity-focused ultrasound in the treatment of primary prostate cancer

An experimental cancer therapy for prostate cancer may be able to treat men without surgery and offer fewer side effects according to the results of a UK study published in the British Journal of Cancer.

7 Jul 2009

Shire files treatment protocol for Velaglucerase Alfa for Gaucher’s disease

Shire plc has announced that, at the request of the FDA, in view of a potential restriction on the availability of the current approved and marketed treatment for Gaucher’s disease patients, it has filed a treatment protocol for velaglucerase alfa, its enzyme replacement therapy in development for the treatment of Gaucher’s disease.

7 Jul 2009

FDA approves Hologic's permanent contraception system

Hologic, Inc.today announced the U.S. Food and Drug Administration (FDA) has approved the Company's premarket approval (PMA) application for the Adiana permanent contraception system.

From Hologic, Inc. 7 Jul 2009

Muscle damage may be present in some patients taking statins

Structural muscle damage may be present in patients who have statin-associated muscle complaints, found a new study in CMAJ (Canadian Medical Association Journal).

7 Jul 2009

Future of organ transplantation - microscopic beads that create "designer " immune cells

The future of organ transplantation could include microscopic beads that create "designer" immune cells to help patients tolerate their new organ, Medical College of Georgia researchers say.

6 Jul 2009

Discovery of genetic key to breast cancer's ability to survive and spread

New research led by investigators at Memorial Sloan-Kettering Cancer Center (MSKCC) sheds light on a genetic function that gives breast cancer cells the ability to survive and spread to the bone years after treatment has been administered.

6 Jul 2009

A new prostate cancer "homing device" for drug delivery

A new prostate cancer "homing device" could improve detection and allow for the first targeted treatment of the disease. A team of Purdue University researchers has synthesized a molecule that finds and penetrates prostate cancer cells and has created imaging agents and therapeutic drugs that can link to the molecule and be carried with it as cargo.

6 Jul 2009